228 related articles for article (PubMed ID: 30421302)
1. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis.
Kim SH; Cha MK; Kang CI; Ko JH; Huh K; Cho SY; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):285-295. PubMed ID: 30421302
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy.
Kim SH; Cho SY; Kang CI; Seok H; Huh K; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Ann Hematol; 2018 Feb; 97(2):343-350. PubMed ID: 29138886
[TBL] [Abstract][Full Text] [Related]
3. Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases.
Mori M; Tsunemine H; Imada K; Ito K; Kodaka T; Takahashi T
Ann Hematol; 2014 Jun; 93(6):901-11. PubMed ID: 24535696
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia.
Imoto W; Yamada K; Yamairi K; Shibata W; Namikawa H; Yukawa S; Yoshii N; Nakaie K; Hirose A; Koh H; Watanabe T; Asai K; Nakamae H; Kaneko Y; Kawaguchi T; Hino M; Kakeya H
Intern Med; 2020; 59(2):193-198. PubMed ID: 31941869
[TBL] [Abstract][Full Text] [Related]
5. Hemorrhagic Pneumonia Caused by
Huang C; Kuo S; Lin L
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256422
[No Abstract] [Full Text] [Related]
6. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy.
Araoka H; Fujii T; Izutsu K; Kimura M; Nishida A; Ishiwata K; Nakano N; Tsuji M; Yamamoto H; Asano-Mori Y; Uchida N; Wake A; Taniguchi S; Yoneyama A
Transpl Infect Dis; 2012 Aug; 14(4):355-63. PubMed ID: 22283869
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains.
Kim EJ; Kim YC; Ahn JY; Jeong SJ; Ku NS; Choi JY; Yeom JS; Song YG
BMC Infect Dis; 2019 Aug; 19(1):754. PubMed ID: 31462215
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
[TBL] [Abstract][Full Text] [Related]
9. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review.
Garazi M; Singer C; Tai J; Ginocchio CC
J Hosp Infect; 2012 Jun; 81(2):114-8. PubMed ID: 22494851
[TBL] [Abstract][Full Text] [Related]
10. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.
Aisenberg G; Rolston KV; Dickey BF; Kontoyiannis DP; Raad II; Safdar A
Eur J Clin Microbiol Infect Dis; 2007 Jan; 26(1):13-20. PubMed ID: 17200840
[TBL] [Abstract][Full Text] [Related]
11. Genotypic and phenotypic insights into virulence factors of nosocomial Stenotrophomonas maltophilia isolates collected in Bulgaria (2011-2022).
Strateva T; Trifonova A; Stratev A; Peykov S
Acta Microbiol Immunol Hung; 2023 Sep; 70(3):220-230. PubMed ID: 37405903
[TBL] [Abstract][Full Text] [Related]
12. Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study.
Zhu L; Wang L; Zhang Y; Chen R; Li X; Sun J; Zhou D; Zhu M; Zheng X; Li L; Zhu J; Xie M; Yang X; Yu W; Tong H; Zhu H; Xie W; Jin J; Ye X
BMC Infect Dis; 2021 Jul; 21(1):723. PubMed ID: 34332526
[TBL] [Abstract][Full Text] [Related]
13. Stenotrophomonas maltophilia bacteremia in children - A 10-year analysis.
Büyükcam A; Bıçakcıgil A; Cengiz AB; Sancak B; Ceyhan M; Kara A
Arch Argent Pediatr; 2020 Jun; 118(3):e317-e323. PubMed ID: 32470274
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series.
Ebara H; Hagiya H; Haruki Y; Kondo E; Otsuka F
Intern Med; 2017; 56(2):137-142. PubMed ID: 28090041
[TBL] [Abstract][Full Text] [Related]
15. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.
Velázquez-Acosta C; Zarco-Márquez S; Jiménez-Andrade MC; Volkow-Fernández P; Cornejo-Juárez P
Support Care Cancer; 2018 Jun; 26(6):1953-1960. PubMed ID: 29307014
[TBL] [Abstract][Full Text] [Related]
16. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.
Cho SY; Lee DG; Choi SM; Park C; Chun HS; Park YJ; Choi JK; Lee HJ; Park SH; Choi JH; Yoo JH
BMC Infect Dis; 2015 Feb; 15():69. PubMed ID: 25887489
[TBL] [Abstract][Full Text] [Related]
17. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.
Micozzi A; Venditti M; Monaco M; Friedrich A; Taglietti F; Santilli S; Martino P
Clin Infect Dis; 2000 Sep; 31(3):705-11. PubMed ID: 11017819
[TBL] [Abstract][Full Text] [Related]
18. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections.
Chang YT; Lin CY; Lu PL; Lai CC; Chen TC; Chen CY; Wu DC; Wang TP; Lin CM; Lin WR; Chen YH
J Microbiol Immunol Infect; 2014 Feb; 47(1):28-35. PubMed ID: 23040236
[TBL] [Abstract][Full Text] [Related]
19. First report of survival in two patients with hematologic malignancy and Stenotrophomonas maltophilia hemorrhagic pneumonia treated with trimethoprim-sulfamethoxazole-based combination antibiotic therapy.
Penagos SC; Giraldo N; Vallejo C; McEwen O; Hidron A
J Infect Chemother; 2020 Apr; 26(4):397-399. PubMed ID: 31882384
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.
Waters VJ; Gómez MI; Soong G; Amin S; Ernst RK; Prince A
Infect Immun; 2007 Apr; 75(4):1698-703. PubMed ID: 17220304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
